Inclisiran
An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.
Key point
Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.
From: Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease (J Saudi Heart Assoc, 2026) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 7, 9, 18, 14, 13.
New guidelines and consensus this year
- Consensus statement and clinical recommendations on the practical management of lipid-lowering therapy in stroke and transient ischaemic attackNeurologia (Engl Ed)2026 Jul-Aug
- Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular DiseaseJ Saudi Heart Assoc2026
All papers from the last 12 months
183 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Real-world treatment adherence and persistence among patients initiating inclisiran or PCSK9 mAbsAm J Prev Cardiol2026 DecPMID 42828262
- Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials"Int J Cardiol Cardiovasc Risk Prev2026 DecPMID 42774982
- Public availability of trial-design and clinical-context information in contemporary lipoprotein(a)-targeted cardiovascular trials: A cross-sectional meta-research studyAm Heart J Plus2026 NovPMID 42831173
- Inclisiran-will it fulfill its promise?Nutr Metab Cardiovasc Dis2026 NovPMID 42392882Review
- Recurrent In-Stent Restenosis and Accelerated Neoatherosclerosis in a Middle-Aged Woman With High Inflammatory BurdenJACC Case Rep2026 Oct 16PMID 42886143
- Magnetic Particle Imaging of Macrophage Phagocytosis Evaluates Plaque Vulnerability and Therapeutic Efficacy in AtherosclerosisArterioscler Thromb Vasc Biol2026 Oct 15PMID 42877977
- Comparative Cardiovascular Outcomes Associated with Evolocumab Versus Inclisiran Among Patients with Elevated Lipoprotein(a)Am J Cardiol2026 Oct 13PMID 42869405
- Effectiveness and Safety of Target-Specific RNA-Based Lipid-Lowering Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEur J Pharmacol2026 Oct 12PMID 42863556Review
- Lipid-Lowering Effects of Inclisiran in Statin- or PCSK9i Monoclonal Antibody-Intolerant IndividualsJ Am Heart Assoc2026 Oct 6PMID 42757932
- A Comprehensive Review of PCSK9 Inhibitor TherapyJ Cardiovasc Pharmacol2026 Oct 1PMID 42391098Review
More cardiology trends
All specialties →SGLT2 inhibitors in heart failure
Use of SGLT2 inhibitors such as dapagliflozin and empagliflozin across heart failure types.
Cardiac myosin inhibitors
Drugs such as mavacamten and aficamten for hypertrophic cardiomyopathy.
Remote cardiac rehabilitation
Cardiac rehabilitation delivered at home or through digital tools.
Key point: Exercise-based telerehabilitation probably improves cardiorespiratory fitness in adults with CVD but provides no convincing evidence of an antihypertensive effect.
Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
Colchicine in cardiovascular disease
Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.
Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.
Renal denervation
A catheter procedure targeting renal nerves to lower blood pressure.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
inclisiran[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.